Show simple item record

dc.contributor.authorTodt, Daniel
dc.contributor.authorGisa, Anett
dc.contributor.authorRadonic, Aleksandar
dc.contributor.authorNitsche, Andreas
dc.contributor.authorBehrendt, Patrick
dc.contributor.authorSuneetha, Pothakamuri Venkata
dc.contributor.authorPischke, Sven
dc.contributor.authorBremer, Birgit
dc.contributor.authorBrown, Richard J P
dc.contributor.authorManns, Michael P
dc.contributor.authorCornberg, Markus
dc.contributor.authorBock, C Thomas
dc.contributor.authorSteinmann, Eike
dc.contributor.authorWedemeyer, Heiner
dc.date.accessioned2017-02-03T09:50:39Z
dc.date.available2017-02-03T09:50:39Z
dc.date.issued2016-10
dc.identifier.citationIn vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. 2016, 65 (10):1733-43 Guten
dc.identifier.issn1468-3288
dc.identifier.pmid27222534
dc.identifier.doi10.1136/gutjnl-2015-311000
dc.identifier.urihttp://hdl.handle.net/10033/620804
dc.description.abstractHepatitis E virus (HEV) infection can take chronic courses in immunocompromised patients potentially leading to liver cirrhosis and liver failure. Ribavirin (RBV) is currently the only treatment option for many patients, but treatment failure can occur which has been associated with the appearance of a distinct HEV polymerase mutant (G1634R). Here, we performed a detailed analysis of HEV viral intrahost evolution during chronic hepatitis E infections.
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleIn vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.en
dc.typeArticleen
dc.contributor.departmentTwincore Centre of Experimental and Clinical Infection Research; a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover 30625, Germany.en
dc.identifier.journalGuten
refterms.dateFOA2018-06-12T21:41:53Z
html.description.abstractHepatitis E virus (HEV) infection can take chronic courses in immunocompromised patients potentially leading to liver cirrhosis and liver failure. Ribavirin (RBV) is currently the only treatment option for many patients, but treatment failure can occur which has been associated with the appearance of a distinct HEV polymerase mutant (G1634R). Here, we performed a detailed analysis of HEV viral intrahost evolution during chronic hepatitis E infections.


Files in this item

Thumbnail
Name:
Todt et al.pdf
Size:
1.289Mb
Format:
PDF
Description:
Open Access article

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/